Enoxaparin infarction

Moderate Major or minor surgery, age 40-60 years, and no clinical risk factors Major surgery, age less than 40 years, and no clinical risk factors Minor surgery, with clinical risk factor(s) Acutely ill (e.g., myocardial infarction, ischemic stroke, heart failure exacerbation), and no clinical risk factors 10-20 1-2 I o UFH 5000 units SC every 12 hours Dalteparin 2500 units SC every 24 hours Enoxaparin 40 mg SC every 24 hours Tinzaparin 3500 units SC every 24 hours IPC Graduated compression stockings... 

Efficacy and safety oftenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001 358 605. LincoffAM, Califf RM, Van De WerfE etal. Mortality at I year with combination platelet glycoprotein llb/llla inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction GUSTO V randomized trial. JAMA 2002 288 2130. 

Antman EM, McCabe CH, Gurfinkel ER et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) I I B trial. Circulation 1999 100 1593-1601. 

I 9 Antman EM, Cohen M, Radley D, etal, Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI I IB-ESSENCE meta-analysis, Circulation 1999 100 1602-1608. 

Theroux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol... 

Antman EM, McCabe CH, Enrique P, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation 1999 100(15) 1593-601. 

Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braun-wald E, Van de Werf F. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction results of the ENTIRE-Throm-bolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002 105 1642-1649. 

The recently described international ASSENT-3 plus trial evaluated the safety and efficacy of prehospital fibrinolysis with TNK -i-enoxaparin and TNK -i- UFH versus historical controls from ASSENT-3. In the former study, the primary efficacy endpoint of the 30-day incidence of death, myocardial infarction, or in-hospital refractory ischemia tended to favor the enoxaparin group, although the results did not achieve statistical significance (14.2% vs. 17.4% p = 0.08) (46). The efficacy and safety endpoint was the composite of the efficacy endpoint with in-hospital major bleeding or intracranial hemorrhage... 

The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001 358 605-613. 

GRACIA-2 212 TNK/Enoxaparin 3-12hrsto PCI UFH or Aboiximab Equal (3%) PIT better ST resolution infarct size the same... 

---